I have mixed feelings about the news.
On one hand, it's great that they are cutting costs; HOWEVER,
Why did they wait so long. Just before going for FDA approval? Is there something to indicate ALT would not have passed through the FDA? If so, was the potential market was not enough to offset the $5 mil a year costs? Something is wrong with ALT, IMO.
I'm not very smart on biotechs, but once FDA approves, it seems the revenue should relatively quickly offset the annualized cost, if ALT was all it was cracked up to be.
Everyone is taking this news in a positive manner, but should we be? Once again, I agree with cutting costs. I don't necessarily agree with cutting costs related to the product that's closest to approval though. Aren't there any other areas we could look at first?
Just my $.02...comments?
Jody |
